Cancers of the nervous system are clinically challenging tumors that present with varied histopathologies and genetic etiologies. While the prognosis for the most malignant of these tumors is essentially unchanged despite decades of basic and translational science research, the past few years have witnessed the identification of numerous targetable molecular alterations in these cancers. With the advent of advanced genomic sequencing methodologies and the development of accurate small-animal models of these nervous system cancers, we are now ideally positioned to develop personalized therapies that target the unique cellular and molecular changes that define their formation and drive their continued growth. Recently, the National Cancer Institute convened a workshop to advance our understanding of nervous system cancer mouse models and to inform clinical trials by reconsidering these neoplasms as complex biological systems characterized by heterogeneity at all levels.

Original languageEnglish
Pages (from-to)692-699
Number of pages8
Issue number7
StatePublished - Jul 2011


  • Brain tumor
  • Genetically engineered mice
  • Glioma
  • Medulloblastoma
  • Xenograft


Dive into the research topics of 'Report from the fifth national cancer institute mouse models of human cancers consortium nervous system tumors workshop'. Together they form a unique fingerprint.

Cite this